We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adverum Biotechnologies (ADVM - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Adverum Biotechnologies is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ADVM is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADVM's full-year earnings has moved 4.62% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ADVM has returned 78.47% so far this year. Meanwhile, the Medical sector has returned an average of -1.66% on a year-to-date basis. This means that Adverum Biotechnologies is performing better than its sector in terms of year-to-date returns.
Looking more specifically, ADVM belongs to the Medical - Biomedical and Genetics industry, which includes 382 individual stocks and currently sits at #16 in the Zacks Industry Rank. This group has gained an average of 8.25% so far this year, so ADVM is performing better in this area.
ADVM will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adverum Biotechnologies (ADVM - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Adverum Biotechnologies is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ADVM is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADVM's full-year earnings has moved 4.62% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ADVM has returned 78.47% so far this year. Meanwhile, the Medical sector has returned an average of -1.66% on a year-to-date basis. This means that Adverum Biotechnologies is performing better than its sector in terms of year-to-date returns.
Looking more specifically, ADVM belongs to the Medical - Biomedical and Genetics industry, which includes 382 individual stocks and currently sits at #16 in the Zacks Industry Rank. This group has gained an average of 8.25% so far this year, so ADVM is performing better in this area.
ADVM will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.